How Extracellular Vesicles (EVs) and Secretomes are Advancing Neurological Disorder Treatments

Neurological disorders such as Alzheimer’s, Parkinson’s, and stroke present challenges in treatment due to the blood-brain barrier and complex disease mechanisms. Recent research highlights extracellular vesicles (EVs) and secretomes as transformative tools in therapeutic development. EVs, including exosomes, act as natural carriers of proteins, RNA, and lipids, facilitating targeted drug delivery to neural tissues with minimal immune response. The parallels between therapeutic strategies for cancer and neurological disorders underscore the versatility of EVs and secretomes. Leveraging these natural delivery systems could revolutionize how we approach complex diseases, from crossing the blood-brain barrier to penetrating solid tumors, making them promising candidates for future breakthroughs.Secretomes, the collection of bioactive molecules secreted by cells, further enhance neuroprotection and repair. These secreted factors include growth factors, cytokines, chemokines, extracellular vesicles (EVs), and other molecules that collectively influence the cellular environment. Their neuroprotective effects have been demonstrated through a variety of preclinical studies.For example:

• In vitro studies: Secretomes derived from mesenchymal stem cells (MSCs) have been shown to modulate inflammation by reducing the expression of pro-inflammatory cytokines (e.g., TNF-α and IL-1β) in microglial cells and increasing anti-inflammatory markers such as IL-10. These studies also demonstrate their role in promoting neurogenesis, with increased neuronal differentiation observed in neural precursor cells exposed to MSC-derived secretomes.
• Animal models: In vivo studies have shown that secretomes, particularly MSC-derived EVs, reduce neural damage and improve functional outcomes in rodent models of neurodegenerative diseases and stroke. For example, intravenous or intracerebral administration of MSC-derived EVs in ischemic stroke models significantly reduced infarct volume and enhanced motor function recovery. These EVs have also been shown to cross the blood-brain barrier, delivering therapeutic cargo such as miRNAs and proteins that regulate neuroinflammation and repair processes.

In animal studies, secretomes are typically administered via routes such as intravenous injection, intrathecal administration, or direct intracerebral delivery. The choice of route depends on the specific disease model and therapeutic goal, with systemic administration often preferred for its less invasive nature and potential for broad biodistribution.These findings highlight the potential of secretomes and EVs as innovative therapeutic approaches for neurodegenerative diseases, underscoring their ability to modulate inflammation, support neurogenesis, and promote cellular regeneration in both experimental and potentially clinical settings.These biomanufactured solutions also offer biocompatible, scalable platforms ideal for clinical applications. With advancements in nanotechnology, EVs are being tailored to improve biodistribution and therapeutic efficacy, setting the stage for next-generation treatments.